ITI Pharma & Healthcare Fund - Growth - Direct Plan

Other Plans and Options
  • 2.52 %Nav, as on 11-04-2025

  • Previous Nav

  • Net Change on 11-04-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
Nifty Healthcare Index - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 10.18 17.60 23.51 0.91 8,080.97
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - Cumulative Option Jul 13, 2018 15.44 21.73 26.00 1.11 4,914.64
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 16.11 22.55 25.87 0.97 3,610.51
DSP Healthcare Fund - Direct Plan - Growth Nov 30, 2018 11.70 18.98 25.77 0.63 3,018.76
Mirae Asset Healthcare Fund Direct Growth Jul 02, 2018 13.09 17.19 24.65 0.52 2,667.40

Fund Holdings as on 31-March-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Lupin Limited

  • Suven Pharmaceuticals Limited

  • Apollo Hospitals Enterprise Limited

  • Max Healthcare Institute Limited

  • Torrent Pharmaceuticals Limited

  • Aurobindo Pharma Limited

  • Mankind Pharma Limited

  • Alkem Laboratories Limited

  • Aster DM Healthcare Limited

  • Abbott India Limited

  • Neuland Laboratories Limited

  • Net Receivables / (Payables)

  • Granules India Limited

  • Dr. Reddy's Laboratories Limited

  • Wockhardt Limited

  • Healthcare Global Enterprises Limited

  • Supriya Lifescience Limited

  • Fortis Healthcare Limited

  • Sumitomo Chemical India Limited

  • FDC Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Rainbow Childrens Medicare Limited

  • Orchid Pharma Limited

  • Caplin Point Laboratories Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Gland Pharma Limited

  • Emcure Pharmaceuticals Limited

  • Sai Life Sciences Limited

  • Vijaya Diagnostic Centre Limited

  • Cipla Limited

  • Onesource Specialty Pharma Limited

  • Shilpa Medicare Limited

  • SRF Limited

  • UPL Limited

  • Linde India Limited

  • Sequent Scientific Limited

  • Strides Pharma Science Limited

  • Laurus Labs Limited

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Pesticides & Agrochemicals

  • Miscellaneous

  • Chemicals

  • Industrial Gases & Fuels

View More

Fund Manager

  • Cash

  • Equity

View More

About ITI Pharma & Healthcare Fund

Scheme Analysis

ITI Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ITI Mutual Fund. It was launched on 08-Nov-2021 and currently has an AUM of ₹213.78 crore. ITI Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and Nifty Healthcare Index - TRI as secondary index.

The NAV of ITI Pharma & Healthcare Fund ended up ₹0.4(2.52%)yesterday to ₹16.3227.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The ITI Pharma & Healthcare Fund is managed by Dhimant Shah and Rohan Korde.

Fund House Contact

ITI House, 36, R K Shirodkar Marg, Parel Mumbai - 400 012

022-69153500
mfassist@itiorg.com
www.itiamc.com